The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy

• Published in: Frontiers in immunology Vol. 12; p. 731751
• Main Authors: Wang, Zeyu, Liu, Yuze, Mo, Yuyao, Zhang, Hao, Dai, Ziyu, Zhang, Xun, Ye, Weijie, Cao, Hui, Liu, Zhixiong, Cheng, Quan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.09.2021
• Subjects: Antineoplastic Agents - therapeutic use; Brain Neoplasms - drug therapy; Brain Neoplasms - genetics; Brain Neoplasms - immunology; Brain Neoplasms - metabolism; Chemokines, CXC - genetics; Chemokines, CXC - metabolism; chemotherapy; Clinical Decision-Making; CXCL; Databases, Chemical; Databases, Genetic; Gene Expression Profiling; Glioma - drug therapy; Glioma - genetics; Glioma - immunology; Glioma - metabolism; gliomas; Humans; immune checkpoint genes; Immunology; immunosuppressive; Nomograms; Predictive Value of Tests; Prognosis; Risk Assessment; Risk Factors; Thiazoles - therapeutic use; Transcriptome; Tumor Microenvironment - immunology; CXCL; immunosuppressive; immune checkpoint genes; gliomas; chemotherapy

Gliomas are a type of malignant central nervous system tumor with poor prognosis. Molecular biomarkers of gliomas can predict glioma patient’s clinical outcome, but their limitations are also emerging. C-X-C motif chemokine ligand family plays a critical role in shaping tumor immune landscape and mo...